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Synthetic ion channels may have applications in treating channelopathies and as new classes of antibiotics,
particularly if ion flow through the channels can be controlled. Here we describe triazole-capped octameric
a-aminoisobutyric acid (Aib) foldamers that “switch on” ion channel activity in phospholipid bilayers upon
copper(II) chloride addition; activity is “switched off” upon copper(II) extraction. X-ray crystallography
showed that CuCl2 complexation gave chloro-bridged foldamer dimers, with hydrogen bonds between
dimers producing channels within the crystal structure. These interactions suggest a pathway for
foldamer self-assembly into membrane ion channels. The copper(II)-foldamer complexes showed
antibacterial activity against B. megaterium strain DSM319 that was similar to the peptaibol antibiotic
alamethicin, but with 90% lower hemolytic activity.Introduction
Natural ion channels carry out key functions in cellular
membranes, including chemical and electrical signal trans-
duction, control of cell volume, andmaintenance of internal ion
concentrations.1 Ion channel function is necessarily tightly
regulated, as unregulated function can result in a disease state.
Many diseases, such as epilepsy, myotonia, ataxia cardiac,
arrhythmia, and cystic brosis, arise because of ion channel
dysfunctions (channelopathies).2,3
Articial ion channels are less structurally complex than
natural protein ion channels,4 so their behaviour can be more
easily analysed. Furthermore, synthetic ionophores could
potentially alleviate the symptoms of channelopathies5,6 or
provide new antibiotic classes able to overcome the growingnchester, Oxford Road, Manchester M13
iversity of Manchester, 131 Princess St,
ty of Edinburgh, Joseph Black Building,
K
antock's Close, Bristol BS8 1TS, UK
Royal Inrmary, Manchester University
L, UK
dical Sciences, University of Manchester,
SI) available: Synthetic procedures and
BC procedures and data. Antibacterial
ography data. CCDC 1999499–1999501.
F or other electronic format see DOI:
of Chemistry 2020problem of resistance.7 Of the wide range of articial ion
channels developed and studied,8 several show either cation
selectivity9 or anion selectivity.10 However, a signicant chal-
lenge in the eld is to “switch” any channel activity,11 so that,
like natural examples, activity can be controlled by external
stimuli, such as light or chemical messengers. Closing channels
by blocking the lumen with an added ligand is known, but
examples of ligand-induced channel opening are less
common.12 These have typically involved ligand-mediated self-
assembly of channels in a membrane; for example, dialkox-
ynaphthalene addition to rigid-rod p-octiphenyl staves gave
weakly anion selective channels.13 Metal ions, such as palla-
dium(II), have also been used to assemble channels within
membranes.10a,14,15,16 Alternatively, multivalent ligands outside
the membrane can drive the lateral assembly of individual
membrane-spanning staves. This was elegantly shown by Matile
and co-workers, who used coordination of external poly-
histidine to copper(II)(iminodiacetate)-terminated p-septi-
phenyls to open K+-selective channels.17
a-Aminoisobutyric acid (Aib) foldamers have recently shown
promise for synthetic ion channel18 and signal transduction
activities.19 These highly hydrophobic foldamers contain high
proportions of Aib, a residue that favours folding into 310 helices.20
Simple Aib foldamers in phospholipid bilayers show length-
dependent ion channel and antibiotic activity,18 with properties
that mimic the ionophoric behaviour of the Aib-rich antimicrobial
peptide alamethicin, the archetypical peptaibol.21 These easy-to-
modify Aib foldamers make an interesting platform for devel-
oping switchable ionophores that may also show antibacterial
activity. For example, Cu(II)-capped Aib foldamers might clusterChem. Sci.
Scheme 1 Synthesis of Aib foldamers 1, 2 and 7 and their corre-
sponding copper(II) chloride complexes.
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View Article Onlineupon binding to an external polyvalent ligand (e.g. polyhistidine),22
perhaps “switching on” ion channel activity that is reversible by
ligand sequestration. Alternatively, Cu(II) complexationmight itself
promote self-assembly into active ion channels.15
The design of the Cu(II) complexing Aib foldamers 1 and 2
(Fig. 1) combines structural elements from previous studies.
Since the ionophoric activity of Aib foldamers is strongly length-
dependent, an octameric (Aib8) foldamer was used as the core,
which had been found to be theminimum length needed to give
good activity.18b This hydrophobic octamer would fold into
a 1.6 nm long 310 helix, which would be capped at the N-
terminus by an N,N-bis(pyridin-20-ylmethyl)-N-((1,2,3-triazol-4-
yl)methyl)amine (BPTA) chelator unit. The tetrameric Aib fol-
damer 7 would provide a shorter control compound. We have
shown that the structurally related N,N-bis(quinolin-2-
ylmethyl)-N-((50-carboxypyridyl)methyl)amine (BQPA) motif at
the N-terminus of foldamers complexes tightly to Cu(II) and
Zn(II).19b,23 Much like related N,N,N-tris(pyridin-2-ylmethyl)
amine (TPA) complexes,24 the BPTA group should adopt
a trigonal pyramidal geometry around the metal ion with at
least one potential coordination site for external ligands. It
should also be accessible in one synthetic step from readily
available Aib foldamers with an N-terminal azido group but
different C-terminal groups. Since hydrophobic groups at the C-
terminus generally enhance the activity of foldamers in phos-
pholipid vesicles and bacteria,18a foldamers 1 and 2 bear
respectively a tBu and a CH2CH2SiMe3 terminus.Results and discussion
Synthesis
Octameric Aib foldamers 3 and 4 were produced by a modication
of previous synthetic procedures.25 Copper-catalysed azide–alkyne
cycloaddition chemistry26 was then used to produce the BPTA
chelator unit at the N-terminus and give target compounds 1 and 2
(Scheme 1). Tetrameric Aib foldamer 7 was produced from 5 using
a similar procedure, providing the control compound with a much
shorter membrane-active unit (the “stave”).
Mixing 1 or 2 with CuCl2 or CuCl provided green or blue
complexes respectively. The green complexes with CuCl2,
proposed to be Cu[1]Cl2 and Cu[2]Cl2, displayed relatively high
solubility in water that was unlike other octameric Aib fol-
damers. The blue complexes from the addition of CuCl gave
very broad NMR spectra even aer preparing fresh samples,
which was ascribed to in situ oxidation of Cu(I); Cu(I)(TPA)Fig. 1 Structure of Aib foldamers 1 and 2.
Chem. Sci.complexes are very efficient one electron donors and will rapidly
reduce alkyl halides27 and oxygen.28 Furthermore these blue
products gave green solids when dried (see the ESI, Fig. S2†).X-ray crystallography
Crystal structures were obtained for three compounds: fol-
damer 2, the green complex from the addition of CuCl2 to 2 and
the blue complex from the addition of CuCl to 2. The solid state
structure of 2 shows a 310 helical structure in the foldamer body
(Fig. 2a) and a head-to-tail distance of 2.1 nm, which is too short
to easily span the hydrophobic width of a typical bilayer (e.g. for
a typical EYPC/cholesterol bilayer, ca. 2.8 nm).29
The green complex, Cu[2]Cl2, that resulted from the addition
of CuCl2 to 2 crystallized as a dimer of foldamers (Fig. 2b). Two
octahedral metal centres share two chloride ligands to give
a dimer with a 3.5 nm end-to-end length between the C-termini
of the linked 310 helices. The screw sense of the Aib helix inverts
at the dicopper centre. The copper ions show a Jahn–Teller
distortion that is consistent with Cu(II), with elongation of one
Cu–Cl bond (2.836(2) A˚) compared to the other (2.241(2) A˚); this
distortion around the Cu(II) centres is similar to that reported in
a [Cu(II)[Ph-TPA](m-Cl)]2Cl2 complex.30 Electron paramagnetic
resonance (EPR) data also showed that unpaired electrons were
present (consistent with Cu(II)). The Cu(BPTA) interacts with the
foldamer body through a hydrogen bond between the triazole
N2 and the NH of Aib(3). A head-to-tail intermolecular hydrogen
bond between dimers (from the NH of Aib(2) to the C]O of
Aib(7)) along with side-to-side packing of the dimers in the solid
state produces channels (Fig. 2d) that run through the crystal
and were lled with disordered electron density. The counter-
ions of the dimeric Cu(II) complex were not located crystallo-
graphically, but an extra chloride was identied by elemental
analysis. It is proposed that these chloride anions are located
(along with solvent) in a region of disordered electron density
that lies in the channels behind the cationic headgroups.
The solid state structure was also determined for crystals
obtained from the pale blue product that resulted from CuCl
addition to 2. The bond lengths around the metal ion indicate
that a copper(II) centre and not a copper(I) centre is present (see
ESI†). The copper complex has a trigonal bipyramidal geometry,
with the copper displaced outwards from the pocket by 0.322 A˚,
a Cu–Cl bond length of 2.203(3) A˚ and a copper to central
nitrogen distance of 2.055(8) A˚. In this structure, the counterionThis journal is © The Royal Society of Chemistry 2020
Fig. 2 (a and b) X-ray crystal structures of (a) 2, (b) [Cu(II)[2](m-Cl)]2Cl2
and (c) [Cu(II)[2]Cl]$HCO3, with bicarbonate ion indicated (boxed). (d)
Channels within the X-ray crystal structure of [Cu(II)[2](m-Cl)]2Cl2.
Fig. 3 (a and b) HPTS assays of (a) MeOH (), 1 ( ), Cu(II)[1]Cl2 ( ) and (b)
MeOH (), 2 ( ) and Cu(II)[2]Cl2 ( ) (all 10 mM except Cu(II)[2]Cl2 6 mM) in
phospholipid vesicles (760 mM lipid) in the presence of KCl (100 mM).
Compounds added at 0 min, base pulse at 1 min, TX-100 added at
7 min allows data normalisation. (c) Switching of ionophoric activity for
1 (10 mM) and 2 (6 mM) in the presence of KCl (100 mM); CuCl2 addition
(2 eq.) at 120 s followed by EDTA addition (2.2 eq.) at 180 s.
Compounds added at 0 min, base pulse at 1 min, TX-100 added at
7 min allows data normalisation. The corresponding data for the
addition of MeOH (20 mL) has been subtracted from these data in (c).
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View Article Onlineis located (boxed, Fig. 2c). Bicarbonate is found in a region of
disordered electron density behind the N-terminal headgroup,
where it is hydrogen bonded to both the NH of Aib(2) and the
NH of Aib(3) in the foldamer body. This counterion is proposed
to result from hydroxide formation during aerial oxidation of an
intermediate Cu(I) complex,28 followed by sequestration of CO2.
The foldamer body shows a hydrogen bond between the triazole
N2 and the NH of Aib(4). The helix displays a mixture of a 310-
and a-helical structure that leads to a shorter end-to-end length
of 1.9 nm compared the parent foldamer 2.31 The observation of
this monomeric species suggests that the formation of the m-Cl
bridged dimer occurs through a reversible process, which would
be inuenced by the surrounding environment.
Ionophoric activity
The membrane activity of 1, 2, Cu[1]Cl2 and Cu[2]Cl2 was assessed
in phospholipid vesicle membranes using 8-hydroxypyrene-1,3,6-This journal is © The Royal Society of Chemistry 2020trisulfonate (HPTS) assays. HPTS assays can show ionophoric
activity that occurs via any combination ofM+/H+ antiport, X/OH
antiport, M+/OH symport and X/H+ symport.
The HPTS assays of 1, 2, Cu[1]Cl2 and Cu[2]Cl2 used 1 : 4
cholesterol : egg yolk phosphatidylcholine (EYPC) vesicles in
MOPS buffer (pH 7.4) with 100 mM of an appropriate salt (e.g.
KCl, KBr, NaCl), following previously reported procedures.16 The
resulting normalised data were tted to pseudo rst-order rate
equations as an approximation (see the ESI†).32 Although the
change in uorescence aer the “burst phase” is likely to arise
from multiple processes, including inter-vesicle transfer of fol-
damers,33 this tting allows the relative effectiveness of each
compound to be compared.
At 10 mM foldamer, ion transport by the parent foldamers 1
and 2 was just above the leakage rate cause by addition of the
methanol control (an observed constant rate constant, kobs, of 1
 103 s1, Fig. 3a and b). For example, in the presence of KCl,
kobs was 3  103 s1 for compound 1 and 3.3  103 s1 for
compound 2. The kobs values for 1 and 2 in the presence of KBr,
KNO3 and NaCl were similar to, or less than, kobs for KCl (see theChem. Sci.
Fig. 4 Ionophoric activity of Cu(II)[2]Cl2 (6 mM) determined through
HPTS assays in the presence of different salts (all 100 mM): (a) KCl ( ),
NaCl ( ), LiCl ( ), RbCl ( ); (b) KCl ( ), KI ( ), K2SO4 ( ), KBr ( ), KNO3 ().
Compounds added at 0 min, base pulse at 1 min, TX-100 addition at
7 min allows data normalisation.
Fig. 5 Lucigenin assays of Cl transport by MeOH (), 2 (10 mM, ) and
Cu(II)[2]Cl2 (10 mM, ) with interior NaNO3 (200 mM) and exterior NaCl
(2 M). Compounds added at 0 min, NaCl added at 1 min, TX-100
addition at 7 min allows data normalization.
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View Article OnlineESI†). The CH2CH2OSiMe3 C-terminus (in 2) led to higher
activity than the tBu C-terminus (in 1), an effect that has
previously been noted for other Aib foldamers.18a
The Cu(II) complexes displayed markedly higher activity than
the parent foldamers; Cu(II)[1]Cl2 (10 mM) showed ca. 5-fold
higher ionophoric activity for KCl transport (kobs ¼ 10.8  103
s1) than 1 aer accounting for background leakage. Cu(II)[2]Cl2
was too active to be accurately measured at 10 mM, therefore the
concentration was reduced to 6 mM. Even at this lower
concentration, Cu(II)[2]Cl2 showed ca. 8-fold higher ionophoric
activity for KCl transport (kobs ¼ 16.5  103 s1) than 2 at 10
mM. Ionophoric activity was dependent on oligomer length, with
the shorter Cu(II)-Aib tetrameric analogue, Cu(II)[7]Cl2, showing
a >50% drop in rate compared to Cu(II)[1]Cl2 (see the ESI†).
Switching of ionophoric activity
The marked difference in activity between 1 and 2 and their cor-
responding Cu(II) species Cu(II)[1]Cl2 and Cu(II)[2]Cl2 provides the
opportunity to “switch” ion transport on and off. “Switching on” of
activity should be induced by addition of CuCl2 to compounds 1
and 2, producing an active Cu(II) species in situ. “Switching off”
ionophoric activity might then be possible by subsequent extrac-
tion of the Cu(II) from foldamer 1 or 2. To demonstrate the
switching of ionophoric activity, the HPTS assay was modied so
that 2 eq. CuCl2 was added at 2min, followed by addition of 2.2 eq.
EDTA at 3 min. As a control, the addition of CuCl2 to a methanol-
containing vesicle suspension (no foldamer present) showedCuCl2
did not signicantly affect the HPTS assay or produce leakage (see
the ESI†).
Both compounds 1 and 2 were “switched on” by CuCl2
addition (Fig. 3c), with a rapid burst of activity that suggests fast
ion transport through pores or channels.10e Subsequent EDTA
addition promptly “switched off” ion transport, only ten
seconds aer EDTA addition (Fig. 3c). The rapid “switch off” of
activity upon the addition of EDTA suggests that the Cu(II)-fol-
damer complexes are not xed at a location deep in the
membrane, as EDTA would not be expected to be able to
partition deep into the hydrophobic region.
Characterisation of ionophoric activity
Comparison of the rates of cation transport by Cu(II)[2]Cl2 (Li
+, Na+,
K+ and Rb+, Fig. 4a) and by Cu(II)[1]Cl2 (Na
+ and K+, see the ESI†)
showed some difference in transport rates for different M+, e.g. kobs
for NaCl was 63% the value of kobs for KCl for Cu(II)[2]Cl2. However
larger rate differences were observed for the transport of anions
(Cl, Br, I, NO3
 and SO4
2) by Cu(II)[2]Cl2, e.g. kobs for KNO3 was
6% of the value for KCl (Fig. 4b). Cu(II)[1]Cl2 shows similar differ-
ences between anions, with kobs for KCl double that of KBr and 5-
fold greater than that of KNO3 (see ESI†).
The addition of a selective proton transporter, carbonyl
cyanide-4-(triuoromethoxy)phenylhydrazone (FCCP) only gave
a very small increase in the rate of transport by Cu(II)[1]Cl2 and
Cu(II)[2]Cl2 (although signicant rate increases were observed
for transport by 1 and 2; see the ESI†). The small effect of FCCP
on Cu(II)[1]Cl2 and Cu(II)[2]Cl2 activity suggests proton transport
is not rate limiting.34Chem. Sci.To conrm that chloride could pass through the bilayers,
lucigenin assays5a were performed for 2, Cu(II)[1]Cl2 and
Cu(II)[2]Cl2 (Fig. 5 and ESI, Fig. S10†). The same lipids were used
as for the HPTS assays and lucigenin was encapsulated with
NaNO3 in the vesicles. Both Cu(II)[1]Cl2 and Cu(II)[2]Cl2 showed
faster Cl transport than 2, albeit with a smaller difference
between 2 and Cu(II)[2]Cl2 than in the HPTS assays (Fig. 5, cf.
Fig. 3). The chloride transport activities are lower than those of
the thioureas developed by Gale, Davis and co-workers35 but
comparable to those of Talukdar and co-workers fumaramides
(up to 40% transport aer 3 minutes at 30 mM fumaramide).36Mechanism of ionophoric activity
Cation/anion carrier,37 ion channel/pore,21a,38 and membrane
disruption mechanisms39 have all been observed for Aib-rich
ionophores, so a series of assays were performed to determine
which mechanism predominated for these foldamers.
To assess if these compounds can act as cation carriers, U-
tube experiments for sodium picrate transport were per-
formed on 1, Cu(II)[1]Cl2 and Cu(II)[2]Cl2. No transport across
the bulk phase was observed for any of these foldamers aer
24 h, unlike the dibenzo-18-crown-6 positive control (see the
ESI, Fig. S11†). Similarly, a U-tube experiment for chloride
transport was performed using lucigenin.4,40 This showed no
chloride was carried through the organic phase by 2, Cu(II)[1]Cl2
and Cu(II)[2]Cl2, unlike the 2-aminopentane positive control
(see the ESI, Fig. S12†). These assays suggest that these AibThis journal is © The Royal Society of Chemistry 2020
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View Article Onlinefoldamers do not predominantly act via an ion carrier
mechanism.
A 5/6-carboxyuorescein (5/6-CF) release assay18b was then
performed to assess if Cu(II)[1]Cl2 and Cu(II)[2]Cl2 disrupt the
membrane or form very large pores able to accommodate the
passage of 5/6-CF (10 A˚ diameter frommolecular modelling).41
Despite high activity in the HPTS assays at 10 mM foldamer, dye
release was insignicant in both cases (see the ESI, Fig. S13†),
indicating that membrane disruption is not extensive.
To assess if the most active compound, Cu(II)[2]Cl2, and its
parent foldamer 2 form channels, planar bilayer conductance
(PBC) studies were carried out. The observation of discrete
conductance events can indicate channel formation and
provide information on the nature of these channels.
PBC experiments were performed in a custom-built cell, with
either 2 or Cu(II)[2]Cl2 (5–10 mL of a 1mMsolution inMeOH) added
to the groundwell. Characterisation sweepswere continued for 2 h,
or until substantial channel-forming activity was observed. Single
channel experiments were conducted under an applied potential of
+100 or 100 mV in 50 s sweeps. Under these conditions, parent
foldamer 2 did not display any ion channel behaviour aer 2 h
under these conditions (see the ESI, Fig. S16†). In contrast, discrete
channel-forming behaviour was observed for Cu(II)[2]Cl2 (Fig. 6a),
with current levels only slightly higher in KCl than in NaCl. Large
current levels and reproducible well-dened quantized steps from
0.5 to 5ms in duration (similar to the “icker” behaviour described
by Chui and Fyles42) were measured (Fig. 6). Greater increases in
macroscopic current value were observed under a negative applied
potential rather than a positive applied potential, which could
suggest a positive charge is being driven into (or through) the
membrane by the applied negative potential; analogous behaviour
has been observed for other channel-forming compounds bearing
positive charges.43 This could imply [Cu(II)[2]Cl]+ cations44 are
involved in the channel-forming species. Channel events haveFig. 6 Step changes in conductance induced by Cu(II) complexes of 2
added to cis side of the membrane. Membranes were formed from
EYPC lipid/cholesterol (4 : 1, w/w) in MOPS buffer at room tempera-
ture (20 mM MOPS, 100 mM NaCl, pH 7.4). Change from 0 pA (grey
bars) indicated by green arrows. Green bars mark the approximate
level of a single quantized current-step. (a) Green complex ([Cu(II)[2](m-
Cl)]2Cl2, final concentration 8.3 mM). (b) Blue complex ([Cu(II)[2]Cl]$
HCO3, final concentration 8.3 mM).
This journal is © The Royal Society of Chemistry 2020multilevel conductances, both at +100 mV (0.08 nS, 0.14 nS)
and at 100 mV potentials (0.08 nS, 0.15 nS).
The I–V curve for Cu(II)[2]Cl2 in KCl is not linear, and shows
sharp increases in conductance as the potential is increased to
+100 mV or 40 mV with a progressive increase in current aer
repeated sweeps between these potentials (see the ESI,
Fig. S17†). The increase in conductance over time may be due to
slow insertion of the foldamer into the membrane, a process
that is accelerated as the potential difference increases (espe-
cially for negative potentials).45
The blue product from the addition of CuCl to 2 was also
assessed using PBC experiments. Under the same conditions
used for Cu(II)[2]Cl2, Cu(II)[2]Cl$HCO3 showed a mixture of
behaviours. Short-lived “icker”-type openings could be
observed, which displayed conductance levels (0.07  0.01 nS,
0.16  0.01 nS, see the ESI†) similar to those observed for
Cu(II)[2]Cl2. In addition, much longer lived “square topped”
openings could also be observed (Fig. 6b). These very regular
well-dened quantized current steps were open for up to 20 ms
at +100 mV, with multiple stepwise increases in conductance
with 0.18 nS increments.46 A linear increase in the conduc-
tance of these current steps was observed with increasingly
positive applied potential, suggesting channels with a symmet-
rical charge distribution are formed (see the ESI†).7b
Application of Hille's equation47 to estimate the inner
channel diameters for both Cu(II)[2]Cl2 and Cu(II)[2]Cl$HCO3
provided approximate pore diameters of 1.5 nm, 2.1 nm and
2.3 nm for the different conductance levels (see the ESI†). These
diameters are comparable to those proposed for different ala-
methicin pores (1.1 nm for hexameric pores; 1.8 nm for octa-
meric pores).38,48Antibiotic activity
Several synthetic ion channels have been shown to exhibit biolog-
ical activity, most commonly in the form of antibiotic activity,
which correlates with ion channel activity in non-biological mem-
branes.8b,10h,14f,49 Long Aibn foldamers (n > 10) show good activity
against the Gram-positive B. megaterium strain DSM319.18a N-
terminal functionalisation of such Aib foldamers with BPTA will
provide a new type of amino terminal Cu(II)- and Ni(II)-binding
(ATCUN)motif, whichmay improve antimicrobial properties.50 Like
other ATCUN motifs, the Cu(II) will be tightly complexed in the
BPTA pocket of 1 and 2 (the stability constant for Cu(II) with TPA is
>1016 M1),50a,51 preventing the release of potentially toxic free Cu(II)
ions into the blood.
The antibiotic activities of 1, 2, Cu(II)[1]Cl2 and Cu(II)[2]Cl2
were measured against B. megaterium strain DSM319 (see the
ESI†). The complexes Cu(II)[1]Cl2 and Cu(II)[2]Cl2 showed much
lower minimum inhibitory concentrations (MICs) than 1 and 2
(Fig. 7a), which correlates inversely with the relative ionophoric
activities measured by HPTS assays. Interestingly, the MIC for
Cu(II)[2]Cl2 is the same within error as that for alamethicin
under the same conditions against this Gram-positive bacterial
strain (alamethicin showed a MIC of 6  2 mM, see ESI†).
Although alamethicin is a very active channel former, its use
in the clinic is hampered by its high haemolytic activity.52 SinceChem. Sci.
Fig. 7 (a) MIC against B. megaterium strain DSM319. (b) Haemolysis of
human erythrocytes caused by alamethicin () and 1 ( ), Cu(II)[1]Cl2 ( ),
2 ( ) and Cu(II)[2]Cl2 ( ).
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
Ju
ne
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/1
/2
02
0 
10
:2
5:
42
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineCu(II)[2]Cl2 shows similar antibiotic activity to alamethicin and
also bears a cationic centre (which oen produce haemolysis),53
its haemolytic activity against human erythrocytes was assessed.
The dose response curve for haemoglobin release gave an EC50
value for haemolysis by alamethicin of 1.4 mM, similar to its
reported EC50 value (1.45 mM in phosphate buffer aer 1 h
incubation).54 Interestingly, all foldamers showed much lower
haemolytic activity under these conditions than alamethicin,
although no EC50 values could be determined for the Aib fol-
damers due to their solubility limits (20 mM for 1 and 2; the
more water soluble Cu(II) complexes produced only 10% hae-
molysis at 25 mM). It is clear however that Cu(II)[1]Cl2 and Cu(II)
[2]Cl2 both produce low haemolysis below 20 mM, despite their
positively charged centres55 and high ionophoric/antibiotic
activity at this concentration. It is known that the haemolytic
activity of amphipathic peptides, including alamethicin,
decreases substantially on a reduction of peptide hydropho-
bicity and hydrophobic moment.56 We suggest that the lower
haemolytic activity of Cu(II)[1]Cl2 and Cu(II)[2]Cl2 compared to
alamethicin is due to their lower hydrophobicity, arising from
the shorter length and the cationic N-termini of the Cu(II)
complexes of 1 and 2, yet ionophoric activity is maintained due
to stronger interactions between foldamers.Conclusions
The chelating Aib foldamers described here show remarkably
efficient “switching” of ion transport activity. As observed for
unfunctionalised Aib octamers,18b BPTA-capped Aib octamers
showed measurable ionophoric activity at micromolar concen-
trations. However complexation to CuCl2 markedly increased
this ionophoric activity, with the Cu(II) complexes showing 5- to
8-fold increases in activity compared to the parent octamers.
There was also clear length dependence, with a shorter Aib
tetramer showing markedly lower activity. Complexation of
Cu(II) was reversible, allowing the ionophoric activity of the Aib
octamers 1 and 2 to be activated in situ by addition of CuCl2 and
deactivated by extraction of the Cu(II) by EDTA. The ionophoric
activity of the CuCl2 complex of 2 approaches that measured for
the archetypical peptaibol alamethicin.18b Channels formed by
these CuCl2/Aib octamer complexes appear to transport both
cations and anions, and showed good chloride transport activityChem. Sci.in lucigenin assays. PBC studies showed square-topped
conductance proles for [Cu(II)[2](m-Cl)]2Cl2 and [Cu(II)[2]Cl]$
HCO3 but no conductance for the parent foldamer 2, consistent
with multimeric ion channel formation by the Cu(II) complexes.
The observation of hydrogen bonds and Cu–Cl–Cu bridges
between foldamers in the solid state (Fig. 2b) indicates the Cu(II)
complexes of the foldamers can form multiple strong inter-
molecular interactions. These interactions will promote self-
assembly of monomeric foldamers into multimeric channels
within the membrane, perhaps aided by the absence of
competing ligands like water and the high effective concentra-
tions that result aer partitioning into the membrane.57 The
solid-state structure of [Cu(II)[2]Cl]$HCO3 also suggests the Aib
foldamer body has a role in facilitating the passage of ions
through the bilayer, and may favour one ion over another. This
structure shows that the bicarbonate counterion is not bound to
the Cu(II) centre but is located behind the headgroup, where it is
hydrogen-bonded to the Aib foldamer body.
The antibiotic activities of 1, 2, Cu(II)[1]Cl2 and Cu(II)[2]Cl2
correlate well with their relative ion channel activity. The MICs
of Cu(II)[1]Cl2 and Cu(II)[2]Cl2 were similar to that of alamethi-
cin. However, these ionophores did not show the high haemo-
lytic activity of alamethicin, a signicant barrier to the adoption
of peptaibols in the clinic.
These Aib foldamers show remarkably efficient switching of
channelling activity upon Cu(II) complexation/decomplexation.
This activity switching in synthetic membranes, although not
easily applied in vivo, may indicate a pathway towards switch-
able non-haemolytic peptaibol antibiotics and switchable drugs
for treating the symptoms of channelopathies.
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